44 Chapter 2 21. Schiffmann, R., et al., Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement. Virchows Archiv : an international journal of pathology, 2006. 448(3): p. 337-343. 22. Linhart, A., et al., Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J, 2007. 28(10): p. 1228-35. 23. Favalli, V., et al., Genetic Screening of Anderson-Fabry Disease in Probands Referred From Multispecialty Clinics. J Am Coll Cardiol, 2016. 68(10): p. 1037-50. 24. Smid, B.E., et al., Uncertain diagnosis of Fabry disease: consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance. Int J Cardiol, 2014. 177(2): p. 400-8. 25. Vedder, A.C., et al., Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS One, 2007. 2(7): p. e598. 26. Biegstraaten, M., et al., Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis, 2015. 10: p. 36. 27. Tomberli, B., et al., Coronary microvascular dysfunction is an early feature of cardiac involvement in patients with Anderson-Fabry disease. Eur J Heart Fail, 2013. 15(12): p. 1363- 73. 28. Kitani, Y., et al., Unexpectedly High Prevalence of Coronary Spastic Angina in Patients With Anderson-Fabry Disease. Circ J, 2019. 83(2): p. 481-484. 29. Vijapurapu, R., et al., Study of indications for cardiac device implantation and utilisation in Fabry cardiomyopathy. Heart (British Cardiac Society), 2019. 105(23): p. 1825-1831.
RkJQdWJsaXNoZXIy MTk4NDMw